Observation on effect of peginterferon α-2a treating lamivudine resistant chronic hepatitis B
10.3760/cma.j.issn.1003-9279.2010.03.023
- VernacularTitle:聚乙二醇干扰素α-2a治疗拉米夫定耐药的慢性乙型肝炎疗效观察
- Author:
Hong-Lian BAI
1
;
Hong-Tao LUO
;
Yi-Nong YE
;
Hui LONG
;
Rui-Xing ZHONG
Author Information
1. 广东省佛山市第一人民医院
- Keywords:
Polyethylene glycols;
Interferon Alfa-2a;
Lamivudine;
Hepatitis B,chronic
- From:
Chinese Journal of Experimental and Clinical Virology
2010;24(3):230-231
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of PEG-interferon α-2a(PEG-IFNα-2a)treatment on lamivudine(LAM)-resistant chronic hepatitis B (CHB)patients.Methods Eighty-one patients with lamivudine-resistant HBeAg (+) chronic hepatitis B patients were enrolled and divided into PEG-IFNα-2a treatment group(40 cases) and adefovir dipivoxil (ADV) control group (41 cases).Two groups were combined with LAM in the first 12 weeks(W).The ALT normalization rate,the HBV DNA and HBeAg negative rate,and the HBeAg seroconversion rate were observed in 12 W,24 W,48 W.Results The ALT normalization rate in 12 W,24 W of PEG-IFNα-2a group was 62.5%and 80.0%.AND it was higher than that of ADV group.The HBeAg negative rate and HBeAg seroconversion rate in 48 W of PEG-IFNα-2a group were 60% and 57.5%,which were higher than that of ADV group.The difference was statistically significant(P<0.05).Conclusion PEG-IFNα-2a treatment of lamivudine-resistant HBeAg (+) chronic hepatitis B is superior to ADV,and its security is well.
